Biogen (BIIB) Tops Q2 EPS by 24c, Offers Guidance

Biogen (NASDAQ: BIIB) reported Q2 EPS of $4.02, $0.24 better than the analyst estimate of $3.78. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.37 billion.

GUIDANCE:

Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.43.

• Total revenue Mid-single digit percentage decline

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight